How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 67.6 | 67.6 | 67.6 | 68.5 | 68.5 | 68.5 | +1.0 |
| Healthcare | 27.5 | 27.5 | 27.5 | 27.6 | 27.6 | 27.6 | +0.1 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 8.71% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| DIVISLAB | Pharma | 5.57% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| AJANTPHARM | Pharma | 4.80% | 8 | 10 | 1 | 3 | 3 | — | +13.9% |
| CAPLIPOINT | Pharma | 3.95% | 10 | 9 | 2 | 4 | 6 | — | +28.9% |
| LUPIN | Pharma | 3.59% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| GLAND | Pharma | 3.56% | 10 | 7 | 5 | 4 | 4 | Leader | +27.9% |
| APOLLOHOSP | Healthcare | 3.46% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| DRREDDY | Pharma | 3.10% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| ALKEM | Pharma | 3.10% | 3 | 8 | 7 | 6 | 8 | — | -6.6% |
| MEDANTA | Healthcare | 2.81% | 8 | 9 | 5 | 4 | 2 | — | +13.1% |
| MAXHEALTH | Healthcare | 2.76% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| IPCALAB | Pharma | 2.68% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| FORTIS | Healthcare | 2.58% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| ANTHEM | Pharma | 2.50% | 10 | 10 | 6 | 3 | 1 | Leader | +16.3% |
| PGHL | Pharma | 2.41% | 4 | 4 | 1 | 8 | 5 | — | -13.0% |
| RAINBOW | Healthcare | 2.34% | 10 | 7 | 4 | 3 | 4 | — | +5.0% |
| SAILIFE | Healthcare | 2.20% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| JLHL | Healthcare | 2.18% | 1 | 9 | 4 | 2 | 10 | — | -83.0% |
| COHANCE | Healthcare | 2.17% | 4 | 5 | 6 | 3 | 5 | — | +1.5% |
| MARKSANS | Pharma | 2.17% | 10 | 6 | 7 | 3 | 6 | Leader | +37.5% |
| GLENMARK | Pharma | 2.11% | 10 | 9 | 9 | 4 | 3 | — | +8.2% |
| VIYASH | Pharma | 1.98% | 8 | 8 | 8 | 6 | 2 | — | +0.3% |
| ASTERDM | Healthcare | 1.94% | 6 | 2 | 9 | 4 | 2 | — | -0.6% |
| AUROPHARMA | Pharma | 1.84% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| SUDEEPPHRM | Pharma | 1.71% | 6 | 9 | 2 | 2 | 1 | — | +76.9% |
| LALPATHLAB | Healthcare | 1.67% | 7 | 8 | 7 | 5 | 3 | — | +18.6% |
| METROPOLIS | Pharma | 1.64% | 8 | 9 | 6 | 7 | 1 | — | +4.7% |
| CIPLA | Pharma | 1.61% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| BIOCON | Pharma | 1.55% | 4 | 1 | 10 | 2 | 7 | — | -8.8% |
| ERIS | Pharma | 1.33% | 3 | 8 | 4 | 9 | 8 | — | -7.4% |
| VIJAYA | Pharma | 1.30% | 7 | 10 | 5 | 4 | 1 | — | +10.1% |
| PFIZER | Healthcare | 1.21% | 5 | 7 | 1 | 8 | 7 | — | -2.9% |
| WINDLAS | Pharma | 1.17% | 9 | 7 | 5 | 1 | 4 | — | +37.4% |
| APLLTD | Pharma | 1.16% | 4 | 5 | 10 | 2 | 9 | — | +2.8% |
| BLUEJET | Pharma | 1.13% | 8 | 10 | 3 | 10 | 4 | — | +21.8% |
| EMCURE | Pharma | 0.99% | 10 | 10 | 9 | 10 | 4 | Leader | +7.6% |
| KIMS | Healthcare | 0.81% | 4 | 3 | 6 | 10 | 2 | — | -9.0% |
| AARTIPHARM | Pharma | 0.73% | 10 | 3 | 4 | 1 | 3 | — | +37.8% |
| ORCHPHARMA | Pharma | 0.73% | 7 | 1 | 4 | 10 | 2 | — | +8.0% |
| JUBLPHARMA | Pharma | 0.61% | 3 | 1 | 3 | 3 | 7 | — | -5.2% |
| SYNGENE | Healthcare | 0.46% | 1 | 2 | 6 | 7 | 7 | — | -17.8% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹203 (+103%), vs ₹156 for Nifty 500 (+56%) and ₹137 for Nifty 50 (+37%). Its relative-strength line ended at 148 vs Nifty 50 and 130 vs Nifty 500 — above 100, sustained outperformance.